Atezolizumab and Bevacizumab Combination Recommended in a Multidisciplinary Consultation Meeting in Caen for Hepatocellular Carcinoma (ABCHCaen)
Launched by UNIVERSITY HOSPITAL, CAEN · May 11, 2024
Trial Information
Current as of March 14, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age superior or equal to 18 years
- • patients with advanced hepatocellular carcinoma
- • treatment validated in multidisciplinary consultation meeting
- Exclusion Criteria:
- • patients with another kind of liver cancer
About University Hospital, Caen
The University Hospital of Caen is a leading academic medical institution dedicated to advancing healthcare through innovative research and clinical trials. As a prominent center for medical education and patient care in Normandy, France, it integrates cutting-edge scientific inquiry with compassionate clinical practice. The hospital collaborates with multidisciplinary teams to conduct rigorous studies aimed at improving treatment outcomes across various medical specialties. By fostering a collaborative environment, the University Hospital of Caen plays a pivotal role in translating research findings into effective therapeutic strategies, ultimately enhancing patient care and contributing to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Caen, France/Normandie, France
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
